| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Thrombosis |
From the INSERM U681 (J.K.-L., E.T., A.-T.G., B.P., E.G., S.V.K., S.L.-D., A.N.), UPMC, Institut des Cordeliers, Paris, France; INSERM E00-16 (G.C., D.U.), Faculté de Médecine Necker-Enfants Malades, Paris, France; Departments of Medicine (E.T.) and Bacteriology (S.M.-P.), Karolinska Institutet, Stockholm, Sweden; and Department of Genetics (R.S.), University of Pennsylvania, Philadelphia.
Correspondence to Antonino Nicoletti, INSERM U681, Institut des Cordeliers 15, rue de lEcole de Médecine, Paris, France. E-mail antonino.nicoletti{at}u430.bhdc.jussieu.fr
| Abstract |
|---|
|
|
|---|
Methods and Results Apolipoprotein E and FVIII doubledeficient mice (E°/FVIII°) were generated. Aortic root lesions were analyzed in 14-week-old and 22-week-old female mice maintained for 8 or 16 weeks, respectively, on a normal chow diet or a hypercholesterolemic diet.
Conclusion Despite a higher plasma total cholesterol concentration compared with E° mice, E°/FVIII° mice developed dramatically less early-stage atherosclerotic lesions. Whereas early lesions in E° mice contained abundant fibrin(ogen) deposits on which few platelets adhered, lesions in E°/FVIII° were almost devoid of fibrin(ogen), and no platelets could be detected. The genotype effect on development and composition of lesions tended to decrease with time. This study demonstrates that the activation of the intrinsic pathway of coagulation is potently proatherogenic at the early stage of atherogenesis.
The contribution of coagulation factor VIII (FVIII)dependent pathway in atherogenesis was addressed in hemophilic apolipoprotein Edeficient mice (E°/FVIII°).
Key Words: atherosclerosis hemophilia mouse knockout
| Introduction |
|---|
|
|
|---|
| Materials and Methods |
|---|
|
|
|---|
Experimental Protocols
Five- to 6-week-old E°/FVIII°, control E°, and FVIII° female mice were placed on a normal chow diet (ND) or a hypercholesterolemic 0.15% cholesterol Western diet (WD) for 8 or 16 weeks (respectively, the "8-week protocol" and the "16-week protocol"). Weights were measured at death. All experiments were approved by our institutional ethical committee.
Plasma Measurements
Citrated blood collected at death was centrifuged at 4°C for 5 minutes at 12 000g, and plasma was stored at 20°C until analysis. Total plasma cholesterol (TC) level was measured using a Boehringer Mannheim kit (France-méthode "CHOD-PAP"). Plasma FVIII activity was measured by a chromogenic assay (Dade-Behring).
Analysis of Atherosclerotic Lesions
After vascular perfusion with sterile PBS, the heart and ascending aorta were dissected. Lesions were quantitated in the aortic sinus as described previously.8 Lesion morphology analysis and immunohistochemistry were performed as described in the Figure 2 legend and the Table.
|
|
| Results and Discussion |
|---|
|
|
|---|
|
Recent studies by B-mode ultrasonography showed that, compared with healthy controls, the extent of intimal lesions in patients with hemophilia was either minimally reduced in the carotid and femoral arteries10 or significantly reduced in the abdominal aorta and leg arteries.11 The discrepancies between these clinical studies might be attributable to the small number of patients available and heterogeneity of treatments (frequency of FVIII infusion, plasma-derived or recombinant FVIII, on-demand or prophylactic treatment). It is important to note that up to 90% of severe hemophilic patients are nowadays under prophylactic FVIII treatment.12 These restraints may hamper the analysis of the impact of FVIII deficiency on atherosclerosis in hemophilia. The mouse model developed in the present study may provide an adequate system to address this issue. We found that regardless of the diet, FVIII° mice developed only small fatty streaks. Despite of higher TC, E°/FVIII° exhibited reduced lesions compared with E° mice (Figure 1B). This effect was dramatic in the 8-week protocol and declined after 16 weeks. Indeed, lesions were respectively 79.0% (ND) and 67.2% (WD) smaller in E°/FVIII° compared with E° mice in the 8-week protocol. In the 16-week protocol, lesions were 26.5% (ND) and 29.8% (WD) smaller in E°/FVIII°. These results show a proatherogenic contribution of the FVIII-dependent intrinsic coagulation pathway, which is prominent during the early stage of atherogenesis and which declines with time.
Next, we aimed at correlating the major difference in lesion size observed in the 8-week protocol between E°/FVIII° and E° mice with differences in platelet content, fibrin(ogen) deposition, and inflammation. Resting and activated platelets were analyzed using antibodies that bind to both. Expression of vascular cell adhesion molecule-1 (VCAM-1) and MAC-3 was considered an index of endothelium activation and macrophage infiltration. In lesions of the double-knockout mice (consistently of the early type), traces of fibrin(ogen) deposition but not platelet adhesion was detected (Figure 2). These lesions contained few macrophages and expressed almost undetectable levels of VCAM-1 (Figure 2; Table). Proteoglycan and collagen deposition in the intimal lesions analyzed by the Periodic acidSchiff/Alcian blue and Sirius red histological staining were not detected in E°/FVIII° mice in the 8-week protocol (Table). In E° mice, fibrin(ogen) deposition was abundant and platelets were found adherent to the lesions (Figure 2). Lesions were also infiltrated by numerous macrophages. VCAM-1 expression was intense (Figure 2; Table) but not restricted to endothelial cells, as reported.13 Therefore, in the 8-week protocol, hypercholesterolemic mice deficient for FVIII developed lesions that were not only smaller but also strikingly different from the FVIII-competent mice.
Plaque composition was studied in the 16-week protocol, a stage in which difference in plaque size between E° and E°/FVIII° mice tended to reduce. VCAM-1, MAC-3, platelet glycoprotein (GP) I
+Iß, and fibrin(ogen) immunolabeling densities were equivalent in E° and E°/FVIII° mice (Table; data not shown). The proteoglycan and collagen contents were equivalent in both groups (Figure 2; Table), indicating that they are not dependent on an operative intrinsic pathway of coagulation at this stage of the disease. Given that it has been proposed recently that the accumulation of erythrocyte membranes within an atherosclerotic plaque may represent a potent atherogenic stimulus14 and that such events were expected to be more frequent in hemophilic atherosclerosis-prone mice, hemosiderin was searched for by the Perls iron method as an indicator of previous hemorrhage. An increased frequency of intraplaque hemorrhages in E°/FVIII° mice would have been expected to contribute to a more severe atherosclerosis according to the concept proposed recently by Kolodgie et al.14 We rather observed a more limited disease. Although iron was deposited in the perivascular myocardium of E°/FVIII° mice, it was not detected in the lesions of the aortic root (data not shown). This indicates that erythrocyte accumulation in the plaque does not contribute to lesion formation in this model. Thus, at later stage of lesion development, the lack of FVIII still exerts an effect on lesion size, but the lesions have a composition proportionately similar in E° and E°/FVIII° mice. These results are in agreement with those reported in atherosclerosis-prone mice deficient for the fibrinogen. Fibrinogen deficiency was reported to decrease the early lesion development in apolipoprotein(a)-transgenic mice15 as well as in E° mice.16 However, in the latter study, the effect is less patent because the earliest time point at which lesions were evaluated is 22 weeks of age.
In conclusion, this study shows that the intrinsic pathway of coagulation is critically involved in the early phase of atherogenesis. The activation of this pathway is clearly proatherogenic at the stage of fatty streak. It has been proposed that platelets that adhere to the arterial wall in vivo in the absence of endothelial cell denudation can locally release preformed inflammatory mediators on GPIIb-IIIa signaling.17 Such mediators alter the inflammatory phenotype of the endothelium by enhancing its expression of adhesion receptors and of chemokines18 that initiate monocyte recruitment. At the early stage of lesion development in hemophilic hypercholesterolemic mice, we did not find platelets adherent to the vessel wall, and VCAM-1 expression was significantly low. Therefore, we may speculate at this stage that platelet adhesion is predominantly dependent on the intrinsic pathway of coagulation. Consequently, FVIII deficiency resulted in a limited inflammation in the vessel wall. Further studies on atherosclerosis-prone mice deficient for a factor of the extrinsic pathway will be necessary to verify that this coagulation pathway is not involved in the early stage of lesion formation. At a later stage, the impact of the intrinsic pathway seems to decline, and the absence of FVIII does not lead to a difference in lesion composition but rather induces a delay in the progression of the disease. This might be an indication that limited but chronic inflammation and tissue damage with the release of tissue factor can ultimately activate the extrinsic pathway in hemophilic mice (FVIII deficiency lowers clotting efficiency but does not neutralize clot formation). Once activated, the extrinsic pathway might trigger platelet activation intricately associated with a chronic inflammation, which is then independent of the intrinsic pathway.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received February 23, 2005; accepted May 12, 2005.
| References |
|---|
|
|
|---|
2. Ananyeva NM, Kouiavskaia DV, Shima M, Saenko EL. Intrinsic pathway of blood coagulation contributes to thrombogenicity of atherosclerotic plaque. Blood. 2002; 99: 44754485.
3. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci U S A. 1992; 89: 44714475.
4. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992; 71: 343353.[CrossRef][Medline] [Order article via Infotrieve]
5. Tangirala RK, Rubin EM, Palinski W. Quantitation of atherosclerosis in murine models:correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J Lipid Res. 1995; 36: 23202328.[Abstract]
6. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH. Targeted disruption of the mouse factor VIII gene produces a model of hemophilia A. Nat Genet. 1995; 10: 119121.[CrossRef][Medline] [Order article via Infotrieve]
7. Bi L, Sarkar R, Naas T, Lawler AM, Pain J, Shumaker SL, Bedian V, Kazazian HH. Further characterization of factor VIII-deficient mice created by gene targeting:RNA and protein studies. Blood. 1996; 88: 34463450.
8. Nicoletti A, Kaveri S, Caligiuri G, Bariety J, Hansson GK. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest. 1998; 102: 910918.[Medline] [Order article via Infotrieve]
9. Cai SR, Motoyama K, Shen KJ, Kennedy SC, Flye MW, Ponder KP. Lovastatin decreases mortality and improves liver functions in fulminant hepatic failure from 90% partial hepatectomy in rats. J Hepatol. 2000; 32: 6777.[Medline] [Order article via Infotrieve]
10. Sramek A, Reiber JH, Gerrits WB, Rosendaal FR. Decreased coagulability has no clinically relevant effect on atherogenesis:observations in individuals with a hereditary bleeding tendency. Circulation. 2001; 104: 762767.
11. Bilora F, Boccioletti V, Zanon E, Petrobelli F, Girolami A. Hemophilia A, von Willebrand disease, and atherosclerosis of abdominal aorta and leg arteries:factor VIII and von Willebrand factor defects appear to protect abdominal aorta and leg arteries from atherosclerosis. Clin Appl Thromb Hemost. 2001; 7: 311313.
12. Plug I, van der Bom JG, Peters M, Mauser-Bunschoten EP, de Goede-Bolder A, Heijnen L, Smit C, Zwart-van Rijkom JE, Willemse J, Rosendaal FR. Thirty years of hemophilia treatment in the Netherlands, 19722001. Blood. 2004; 104: 34943500.
13. Laurat E, Poirier B, Tupin E, Caligiuri G, Hansson GK, Bariety J, Nicoletti A. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation. 2001; 104: 197202.
14. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, Guerrero LJ, Hayase M, Kutys R, Narula J, Finn AV, Virmani R. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med. 2003; 349: 23162325.
15. Lou XJ, Boonmark NW, Horrigan FT, Degen JL, Lawn RM. Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice. Proc Natl Acad Sci U S A. 1998; 95: 1259112595.
16. Xiao Q, Danton MJ, Witte DP, Kowala MC, Valentine MT, Degen JL. Fibrinogen deficiency is compatible with the development of atherosclerosis in mice. J Clin Invest. 1998; 101: 11841194.[Medline] [Order article via Infotrieve]
17. Massberg S, Brand K, Gruner S, Page S, Muller E, Muller I, Bergmeier W, Richter T, Lorenz M, Konrad I, Nieswandt B, Gawaz M. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med. 2002; 196: 887896.
18. Gawaz M, Neumann FJ, Dickfeld T, Koch W, Laugwitz KL, Adelsberger H, Langenbrink K, Page S, Neumeier D, Schomig A, Brand K. Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation. 1998; 98: 11641171.
This article has been cited by other articles:
![]() |
H. M.H. Spronk Vitamin K Epoxide Reductase Complex and Vascular Calcification: Is This the Important Link Between Vitamin K and the Arterial Vessel Wall? Circulation, March 28, 2006; 113(12): 1550 - 1552. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |